BioLineRx Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the t… Read more
BioLineRx Ltd (BLRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.108x
Based on the latest financial reports, BioLineRx Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.108x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.11 Million) by net assets ($19.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioLineRx Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how BioLineRx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioLineRx Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioLineRx Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enero Group Ltd
AU:EGG
|
0.009x |
|
Green Packet Bhd
KLSE:0082
|
0.221x |
|
Hanryu Holdings, Inc. Common Stock
NASDAQ:HRYU
|
-0.016x |
|
Alpine Select AG
SW:ALPN
|
-0.011x |
|
Abans Holdings Limited
NSE:AHL
|
0.000x |
|
Creas F&C Co.Ltd
KQ:110790
|
-0.010x |
|
Cagdas Cam Sanayi ve Ticaret A.S.
IS:CGCAM
|
N/A |
|
ORIGIN MATER. A DL-0001
F:5ER
|
N/A |
Annual Cash Flow Conversion Efficiency for BioLineRx Ltd (2008–2024)
The table below shows the annual cash flow conversion efficiency of BioLineRx Ltd from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.46 Million | $-43.87 Million | -3.259x | -90.63% |
| 2023-12-31 | $13.22 Million | $-22.61 Million | -1.710x | -231.27% |
| 2022-12-31 | $50.84 Million | $-26.24 Million | -0.516x | -49.07% |
| 2021-12-31 | $68.09 Million | $-23.57 Million | -0.346x | +67.13% |
| 2020-12-31 | $22.03 Million | $-23.21 Million | -1.053x | -55.13% |
| 2019-12-31 | $33.38 Million | $-22.67 Million | -0.679x | -15.98% |
| 2018-12-31 | $41.32 Million | $-24.19 Million | -0.585x | -50.68% |
| 2017-12-31 | $52.88 Million | $-20.55 Million | -0.389x | +6.22% |
| 2016-12-31 | $35.03 Million | $-14.51 Million | -0.414x | -39.23% |
| 2015-12-31 | $47.61 Million | $-14.17 Million | -0.298x | +34.72% |
| 2014-12-31 | $31.77 Million | $-14.48 Million | -0.456x | +73.68% |
| 2013-12-31 | $11.68 Million | $-20.23 Million | -1.732x | -28.90% |
| 2012-12-31 | $14.97 Million | $-20.11 Million | -1.344x | -169.77% |
| 2011-12-31 | $22.53 Million | $-11.22 Million | -0.498x | -261.89% |
| 2010-12-31 | $37.26 Million | $11.46 Million | 0.308x | +144.52% |
| 2009-12-31 | $31.13 Million | $-21.51 Million | -0.691x | +48.70% |
| 2008-12-31 | $20.75 Million | $-27.96 Million | -1.347x | -- |